Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy

Background Capecitabine is an oral chemotherapeutic agent used in colorectal cancer. Two prior studies found a negative impact with the concomitant use of proton pump inhibitor agents during treatment with capecitabine in patients with early colorectal and gastroesophageal cancers. Objective To determine if there is a clinical impact of the concomitant use of capecitabine and acid suppression therapy in patients with local and metastatic colorectal cancer. Methods This was a single-center retrospective cohort study of adult patients with colorectal cancer on capecitabine monotherapy between 2011 and 2017. Progression-free survival (PFS) and overall survival were compared between patients on acid suppression therapy and those not on acid suppression therapy. Results A total of 70 patients were included. Patients on acid suppression therapy at capecitabine initiation (21%) had decreased progression-free survival versus those not on acid suppression therapy (HR 2.24, 95% CI 1.06–4.41, p = 0.035), after adjusting for disease severity and age. Acid suppression therapy use was associated with a numerical decrease in overall survival (HR 1.86, 95% CI 0.81–3.91, p = 0.14). In patients on any concomitant acid suppression therapy (25%), there was a decreased rate of progression-free survival (HR 6.21, 95% CI 2.56–14.32, p = 0.0001) but not overall survival (HR 1.64, 95% CI 0.68–3.54, p = 0.25) versus those without concomitant acid suppression therapy, after adjusting for age and disease severity. Conclusions Concurrent use of acid suppression therapy and capecitabine was associated with decreased progression-free survival, and there was a trend towards decreased overall survival. Due to the demonstrated potential of decreased efficacy, concurrent use of proton pump inhibitors or histamine 2 receptor antagonists should be avoided in colorectal cancer patients on treatment with capecitabine monotherapy.

Download Full-text

P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients

Annals of Oncology ◽

10.1016/j.annonc.2021.05.184 ◽

2021 ◽

Vol 32 ◽

pp. S142-S143

Author(s):

A. Pretta ◽

M. Persano ◽

G. Pinna ◽

C. Donisi ◽

E. Cimbro ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Progression Free Survival ◽

Braf Mutations ◽

Free Survival ◽

Colorectal Cancer Patients

Download Full-text

Prognostic value of incidental betablockers use in metastatic colorectal cancer patients receiving first-line treatment.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e14610 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e14610-e14610

Author(s):

Michela Del Prete ◽

Riccardo Giampieri ◽

Mario Scartozzi ◽

Elena Maccaroni ◽

Luca Faloppi ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Response Rate ◽

Progression Free Survival ◽

First Line ◽

Free Survival ◽

First Line Therapy ◽

Line Therapy ◽

Colorectal Cancer Patients

e14610 Background: Preclinical and retrospective studies suggested antitumor activity for the incidental use of betablockers in various tumour types. Data regarding colorectal cancer are lacking. We assessed the correlation between the incidental use of betablockers and clinical outcome in colorectal cancer patients receiving first-line therapy. Methods: 235 patients treated with first-line chemotherapy alone (128 patients) and with Bevacizumab (107 patients) were analysed. Patients were stratified for betablockers use, age, sex, site of metastases, previous adjuvant chemotherapy and ECOG performance status. Results: 29 patients (12%) were on treatment with betablockers at the time of first-line therapy: 20 (16%) in the chemotherapy alone group and 9 in the bevacizumab group (8%). In both groups patients receiving or not betablockers were similar for all main clinical characteristics. In the chemotherapy alone group, patients receiving betablockers showed an improved response rate (60% vs. 33%, p=0.044) and overall survival (mOS 41.3 vs 25.7 months, p=0.03, HR:2.26, 95% CI: 1.05-3.24). Only a trend for improved progression free survival was noticed. In the 107 patients receiving chemotherapy with bevacizumab a trend towards a worse overall survival was seen for patients receiving betablockers, although this was not statistically significant (mOS 16 vs 23.7 months, p=0.26, HR:0.64, 95% CI: 0.22-1.49). No significant differences were seen in regards of progression free survival or different response rate patterns between the two groups. Conclusions: Our analysis confirms a potential prognostic role for the use of betablockers in colorectal cancer patients treated with chemotherapy. Our findings are in line with preclinical studies suggesting that beta-adrenergic signalling may regulate cancerogenesis and tumor invasiveness. Our analysis suggests a potential worse outcome for patients on betablockers receiving Bevacizumab-based treatment, although the small number of patients precludes any definitive conclusion. We suggest that in future prospective trials the incidental use of betablockers will be considered a stratification factor for clinical outcome.

Download Full-text

The Prognostic Value of New Index (LANR) Composed of Pre-operative Lymphocytes, Albumin, and Neutrophils in Patients With Resectable Colorectal Cancer

Frontiers in Oncology ◽

10.3389/fonc.2021.610264 ◽

2021 ◽

Vol 11 ◽

Author(s):

Xinjun Liang ◽

Shuang Yao ◽

Ping Lu ◽

Yifei Ma ◽

Hongli Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Prognostic Value ◽

Treatment Plan ◽

Area Under The Curve ◽

Progression Free Survival ◽

Inflammatory Factors ◽

Free Survival ◽

Colorectal Cancer Patients

Background: Inflammatory factors and nutritional status are critical to the prognosis of colorectal cancer patients. This study aimed to investigate the prognostic value of the combination of preoperative lymphocytes, albumin, and neutrophils (LANR) in patients with resectable colorectal cancer.Methods: A total of 753 patients with pathologically diagnosed primary colorectal cancer were included in the study. The value of LANR was defined as follows: LANR, lymphocyte × albumin/neutrophil. The ROC curve, subgroup analysis and Cox proportional hazard regression analysis were used to assess the prognostic value of LANR in overall survival and progression-free survival.Results: The median age of the patients was 60 years (range 52–67 years). In overall survival, the area under the curve of LANR was 0.6276, and the HR (95% CI) was 0.551 (0.393–0.772). And in progression-free survival, the area under the curve of LANR was 0.5963, and the HR (95% CI) was 0.697 (0.550–0.884). The results indicate that preoperative LANR may be a reliable predictor of overall and progression-free survival in resectable colorectal cancer patients.Conclusions: LANR is an important prognostic indicator for patients with resectable colorectal cancer, and it can also provide a reference for clinicians and patients to choose a treatment plan.

Download Full-text

Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience

Annals of Oncology ◽

10.1093/annonc/mdz155.295 ◽

2019 ◽

Vol 30 ◽

pp. iv81

Author(s):

A. Pretta ◽

E. Lai ◽

N. Liscia ◽

V. Impera ◽

S. Camera ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Progression Free Survival ◽

Single Center ◽

Braf Mutations ◽

Free Survival ◽

Single Center Experience ◽

Colorectal Cancer Patients

Download Full-text

Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2019.368 ◽

2019 ◽

Vol 7 (24) ◽

pp. 4244-4249

Author(s):

Trinh Le Huy ◽

My Hanh Bui ◽

Toi Chu Dinh ◽

Hoang Thi Hong Xuyen

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Survival Rate ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Stage Iv ◽

Progression Free Survival ◽

Overall Survival Rate ◽

Free Survival ◽

Colorectal Cancer Patients

BACKGROUND: In recent times, scientists have found new treatments for colorectal cancer patients. AIM: The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV. METHODS: Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients. RESULTS: The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage. CONCLUSIONS: The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.

Download Full-text

Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02369-1 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Ziyao Li ◽

Shaofei Li ◽

Hangbo Tao ◽

Yixiang Zhan ◽

Kemin Ni ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Hepatitis B ◽

Liver Metastases ◽

Cancer Patients ◽

Hepatic Metastasis ◽

High Titer ◽

Poor Overall Survival ◽

Free Survival ◽

Colorectal Cancer Patients

Abstract Background There have been controversial voices on if hepatitis B virus infection decreases the risk of colorectal liver metastases or not. This study aims to the find the association between HBV infection and postoperative survival of colorectal cancer and the risk of liver metastases in colorectal cancer patients. Methods Patients who underwent curative surgical resection for colorectal cancer between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival, time to progress, and hepatic metastasis-free survival between groups and significant predictors were analyzed. Results Three hundred twenty-seven colorectal cancer patients were comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases were further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). The high-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001), and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than the low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718–7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789–11.842; P < .001), and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054–13.369; P = .041) in the anti-HBc positive cases. Conclusions Higher titer anti-HBc predicts a potential higher risk of liver metastases and a worse survival in anti-HBc positive colorectal cancer patients.

Download Full-text